A major study validates the GOLDEN model as an accurate tool for predicting HBsAg loss in interferon-treated chronic ...
Whether hepatitis resolves depends on the type and whether a person receives treatment. Hepatitis A usually resolves without medications, and while sometimes hepatitis B and C may last only a few ...
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced end-of-treatment data from Part B of the MARCH Phase 2 clinical study evaluating combinations of tobevibart and ...
Chronic hepatitis B (CHB) is a long-term infection of the liver caused by the hepatitis B virus (HBV). While acute hepatitis B infection is often resolved by the immune system, CHB occurs when the ...
Chronic hepatitis B virus (HBV) infection remains a significant global public health challenge, particularly in China and other Asia-Pacific regions. Over the past few decades, China has made ...
Background Withdrawal of prolonged nucleos(t)ide analogue (NA) treatment results in hepatitis B surface antigen (HBsAg) loss in some subjects with chronic hepatitis B (CHB), potentially revealing ...
First CTA authorization marks nChroma's transition to a clinical-stage company; first patient dosing in Phase 1/2 trial planned for early 2026 Preclinical studies demonstrated CRMA-1001 delivers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback